Benperidol

Benperidol, sold under the trade name Anquil among others, is a typical antipsychotic primarily used to treat hypersexuality syndromes and can be used to treat schizophrenia. It is a highly potent butyrophenone derivative and is the most potent neuroleptic in the European market, with chlorpromazine equivalency as high as 75 to 100 (about 150 to 200% the potency per dose of haloperidol). It is sometimes prescribed to sex offenders as a condition of their parole, as an alternative to anti-androgen drugs such as cyproterone acetate.

Benperidol was discovered by Janssen Pharmaceutica in 1961 and has been marketed since 1966. It is mainly used in Germany, but it is also available in Belgium, Greece, the Netherlands, and the United Kingdom.

Pharmacology

Pharmacodynamics

Benperidol is a strong dopamine receptor antagonist ( D₂ (''K''_i 0.027 nM) and D₄ (''K''_i 0.066 nM)) with weaker serotonin receptor antagonism ( 5-HT_2A (''K''_i 3.75 nM)). In high doses, it has antihistaminergic and alpha-adrenergic properties. It possesses minimal anticholinergic properties.

Although benperidol was developed relatively early in the history of antipsychotic drugs, it exhibits a uniquely high and selective affinity for the human dopamine D₂ receptor when compared with all other human dopamine receptor subtypes. This is evident from its nanomolar binding affinities, which stand out even among both typical and atypical antipsychotics. Benperidol is also considered to possess one of the greatest selectivity ratios for dopamine receptors over 5-HT₂A serotonin receptors, although this distinction is surpassed by certain neuroleptics such as amisulpride and sulpiride. Dopamine receptors play central roles not only in cognition, emotion, and motor control—key domains affected in schizophrenia—but also in various unconscious biological processes. The emphasis on D₂ receptor blockade in antipsychotic drug design stems from its critical role in these functions and its dense expression in brain regions implicated in schizophrenia, such as the striatum and frontal cortex. Benperidol’s preferential binding to the D₂ receptor—over other dopamine receptor subtypes such as D₃ and D₄—is also unusually strong, with approximately a twofold greater selectivity. This distinguishes it from antipsychotics like haloperidol and perphenazine, which show more balanced D₂/D₃ binding ratios (e.g., 0.7–0.3 or 0.13), as well as from cariprazine, which demonstrates an even higher D₃ affinity relative to D₂ (D₂–D₃ ratio of 0.49–0.085).

Pharmacokinetics

Benperidol is absorbed well and undergoes extensive first pass metabolism. One percent of benperidol is excreted in urine. The half-life of benperidol is 8 hours.

Synthesis

4-(2-Keto-1-benzimidazolinyl)piperidine (1) is alkylated with 4-chloro-4'-Fluorobutyrophenone (2) to produce benperidol (3). Chemical Abstracts 60, 10690c (1964), corresp. to

See also

* Timiperone has a similar chemical structure with a thiourea group instead of a urea group.
*Pimozide, bezitramide, oxiperomide, and neflumozide) are also made from 4-(1-benzimidazolinone)piperidine precursor
*Droperidol is similar, but has a tetrahydropyridine ring.

References

{{Dopaminergics

Belgian inventions
Benzimidazoles
Butyrophenone antipsychotics
Janssen Pharmaceutica
4-Fluorophenyl compounds
Piperidines
Typical antipsychotics